No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Analysts at Berenberg slightly raised their target price on drugmaker GSK from 16 to 16.60 per share on Tuesday after it hosted chief financial officer Julie Brown for the eighth session of its annual pharma CFO series.
Berenberg satated as CFO in 2026, Brown will be focusing on delivering the financial ambition for the business, with its Blenrep and depemokimab assets being "key commercial drivers" that it believes to be "underappreciated by the market".
The German bank stated the launch of both drugs will be "a key focus for investors into 2026", and said it forecasts 5% total revenue growth, an operating margin of 31% and 8% earnings per share growth in FY26.
"We retain our 'hold' recommendation and raise our price target to GBP16.60, reflecting recent financial performance," said Berenberg.
"GSK trades on 10.3x 2026 adjusted earnings versus European peers on 13.7x. On EV/NPV, GSK trades c12% below European peers (0.80x versus 0.91x) and c21% below the value of marketed assets alone."
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.